Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
34.33
-1.81 (-5.01%)
At close: Oct 30, 2026, 4:00 PM EDT
34.23
-0.10 (-0.29%)
After-hours: Oct 30, 2026, 7:30 PM EDT
Caris Life Sciences Stock Forecast
Stock Price Forecast
According to 14 analysts polled by S&P Global, Caris Life Sciences stock has a consensus rating of "Buy" and an average price target of $32.46. The average 1-year stock price forecast is 5.45% lower than the current stock price, while the lowest is $22 (-35.92%) and the highest is $38 (+10.69%).
Price Target: $32.46 (-5.45%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Caris Life Sciences stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 9 | 9 | 9 | 9 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 3 | 3 | 3 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 14 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Buy Maintains $33 → $38 | Buy | Maintains | $33 → $38 | +10.69% | Oct 27, 2026 |
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $22 → $30 | Hold | Maintains | $22 → $30 | -12.61% | Oct 19, 2026 |
| J.P. Morgan | J.P. Morgan | Buy Maintains $25 → $35 | Buy | Maintains | $25 → $35 | +1.95% | Oct 14, 2026 |
| TD Cowen | TD Cowen | Buy Maintains $30 → $36 | Buy | Maintains | $30 → $36 | +4.86% | Oct 13, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains $23 → $35 | Buy | Maintains | $23 → $35 | +1.95% | Oct 9, 2026 |
Financial Forecast
Revenue This Year
1.03B
from 812.03M
Increased by 26.99%
Revenue Next Year
1.23B
from 1.03B
Increased by 19.44%
EPS This Year
0.14
from -0.41
EPS Next Year
0.37
from 0.14
Increased by 169.49%
EPS and Forward PE are based on non-GAAP adjusted numbers.